The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there is no assurance that the investment objective of the scheme will be achieved. The Scheme does not guarantee/ indicate any returns.
The Scheme will be predominantly invested in equity and equity related securities of healthcare and pharmaceutical companies. The aim of the Scheme is to seek long-term capital appreciation from an actively managed portfolio. The fund may consider investing in various sectors within the healthcare industry, including healthcare services and healthcare manufacturing. Healthcare services include, but are not limited to, pharmacy, diagnostics, hospitals and health insurance. Healthcare manufacturing encompasses CRAMS (Contract Research and Manufacturing Services), medical devices, specialty chemicals, formulations and API (Active Pharmaceutical Ingredient), among others. The portfolio will be built utilizing a combination of top-down and bottom-up portfolio construction process, focusing on the fundamentals of each stock, including quality of management. The Scheme may also invest a certain portion of its corpus in debt and money market securities. Investment in debt securities will be guided by credit quality, liquidity, interest rates and their outlook. The Scheme may invest in other scheme(s) managed by the AMC or in the scheme(s) of any other mutual fund, provided it is in conformity with the investment objectives of the Scheme and in terms of the prevailing Regulations
Top Mutual Funds
